“I am truly delighted to welcome Marie and Loïc to the BIODOL executive team,” said Fabien Granier, Chief Executive Officer of BIODOL Therapeutics. “Their deep scientific and clinical expertise, combined with proven leadership in global pharmaceutical environments, will be instrumental as we enter the next stages of our clinical and strategic roadmap. Together, we are shaping a company committed to bringing safer and more effective therapies to patients living with chronic pain.”
Dr. Marie-Laurence Gourlay-Chu, M.D., brings over 25 years of experience in clinical development, pharmacovigilance and medical affairs across biotechnology and pharmaceutical companies. Prior to joining BIODOL, she served as Chief Medical Officer at PPRS SAS, where she oversaw clinical trials, pharmacovigilance and regulatory strategy for multiple therapeutic areas. Her earlier roles include Medical and Drug Safety Director at Genethon Biotherapy Institute and Senior positions at Ipsen, AstraZeneca and the French Health Products Safety Agency (ANSM) where she served as Head of Drug Information ensuring regulatory compliance and promotion of rational use of medicines. Her therapeutic area focus includes immunology, CNS and rare diseases. At BIODOL, Dr. Gourlay-Chu will lead the company’s global clinical development and medical strategy ensuring scientific and medical expertise and patients’ safety.
Dr. Loïc Laplanche, Ph.D., joins BIODOL following more than 25 years of leadership in non-clinical and translational sciences supporting projects in discovery, preclinical and clinical development stages in global pharmaceutical companies. Most recently, he served as Senior Scientific Director at AbbVie, leading DMPK and regulated bioanalysis organisations and contributing to the non-clinical portfolio strategy across neuroscience, immunology, and oncology for diverse therapeutic modalities. A former researcher at Sanofi-Aventis and project leader in several EU-IMI consortia, Dr. Laplanche brings extensive expertise in non-clinical development, quantitative and translational pharmacology, and cross-functional team management. As COO, he will oversee BIODOL’s operations, partnerships, and scientific programs to drive innovation and execution across the company’s pipeline.
About Biodol Therapeutics
Biodol Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class compounds for pain treatment. The company has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key driver in initiating and sustaining neuropathic pain (Nature Communications, 2018). Its groundbreaking research has also demonstrated that inhibiting FLT3 signaling eliminates opioid tolerance and hyperalgesia while preserving analgesic efficacy (Nature Communications, 2024). Biodol Therapeutics is focused on developing allosteric inhibitors of the FLT3 receptor to address various types of pain. The company holds exclusive rights to a portfolio of four patents and has received support from BPI France, SATT AxLR, Inserm Transfert, Région Occitanie, the French National Research Agency, SEMIA Incubator, and the Montpellier Business and Innovation Centre.
For more information, please contact:
Biodol Therapeutics
contact@biodol.eu
